08/24/2015
HM-100, HealthMed's clinically targeted version of the cardiovascular "polypill" passes FDA pre-IND muster.
The agency extends possibilities for: Three-Year Exclusivity for a New Drug Application that contains sponsored clinical studies essential to its approval;
and: Priority Review for a New Drug Application that includes documented evidence of likely improvements in adherence.